Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
By Barbara Kollmeyer
As times get tough for big tech stocks, Goldman Sachs says investors should look at defensive-type stocks and consumer names like J.M Smuckers.
Now that the tech sector that has powered the stock market is wobbling, what's an investor to do?
Goldman Sachs strategists led by Ben Snider told clients in a note late Friday that they should focus on buying stocks in sectors that haven't done as well.
In particular they recommend consumer-facing stocks, on the view energy prices and interest rates will fall next year, lifting real income growth across consumers. They also favor consumer experience stocks, which they see as cheap and exposed to strong secular growth.
Snider and his team noted that exposure to consumer discretionary companies XLY, which deal in nonessential goods and services, is at multiyear lows among Wall Street hedge funds that have also been trimming exposure to AI-related stocks.
Goldman's basket of low-income consumer discretionary stocks has rallied 7% since October. "In particular, our economists expect that income growth for the bottom income quintile will accelerate notably in 2027 as inflation slows and January cost-of-living adjustments boost transfer payments," they said.
Snider and his team suggested focusing on defensive industry stocks with "quality" attributes.
They offered a screen of 23 Russell 1000 RUI stocks from healthcare and consumer staples poised to outperform if the market continues to pare back on growth, such as Tyson Foods (TSN) and CVS Health (CVS). The stocks are in defensive industries that rank above average when it comes to share-price volatility, free cash flow yield and how well they can convert operating profit into cash:
Healthcare Equipment & Services Name Industry group YTD return 2-week return 12-month realized volatility Trailing fourth-quarter FCF yield TSN Tyson Foods, Inc. Food Beverage & Tobacco -5% 4 % 26 11 % RPRX Royalty Pharma Plc Pharmaceuticals Biotechnology & Life Sciences 56 % 4 % 23 9 % CVS CVS Health Corporation Health Care Equipment & Services 19 % 7 % 31 9 % SJM J.M. Smucker Company Food Beverage & Tobacco 33 % 7 % 28 9 % KR Kroger Co. Consumer Staples Distribution & Retail 2 % 6 % 29 8 % CAH Cardinal Health, Inc. Health Care Equipment & Services 25 % 11 % 30 8 % HCA HCA Healthcare Inc Health Care Equipment & Services 1 % 10 % 31 7 % HRL Hormel Foods Corporation Food Beverage & Tobacco -10% 1 % 29 7 % PFGC Performance Food Group Co Consumer Staples Distribution & Retail 8 % 4 % 29 6 % SYY Sysco Corporation Consumer Staples Distribution & Retail 15 % 6 % 27 6 % KVUE Kenvue, Inc. Household & Personal Products 13 % 9 % 29 6 % HSY Hershey Company Food Beverage & Tobacco -5% 5 % 27 6 % USFD US Foods Holding Corp. Consumer Staples Distribution & Retail 35 % 5 % 30 5 % MRK Merck & Co., Inc. Pharmaceuticals Biotechnology & Life Sciences 41 % 1 % 29 5 % RMD ResMed Inc. Health Care Equipment & Services 1 % 11 % 29 5 % DGX Quest Diagnostics Incorporated Health Care Equipment & Services 40 % 3 % 24 5 % CHE Chemed Corporation Health Care Equipment & Services 21 % 2 % 29 5 % ABT Abbott Laboratories Health Care Equipment & Services -14% 8 % 27 5 % MDLZ Mondelez International, Inc. Food Beverage & Tobacco 20 % 8 % 24 4 % MCK McKesson Corporation Health Care Equipment & Services 22 % 11 % 31 4 % CHD Church & Dwight Co., Inc. Household & Personal Products 24 % 9 % 23 4 % ABBV AbbVie, Inc. Pharmaceuticals Biotechnology & Life Sciences 28 % 8 % 26 4 % CL Colgate-Palmolive Company Household & Personal Products 19 % 10 % 23 4 % List median - - 19 % 7 % 29 6 % Russell 1000 median - - 6 % 2 % 36 4 % Source FactSet, Goldman Sachs Global Investment Research - - - - -
The S&P 500 Index SPX, dominated by big tech companies, last week saw its worst weekly return since late June. Its performance has been increasingly disjoined from the average stock for months, but the divide began heating up in September.
Rising worries about the cost and availability of funding for companies has pushed investors to cut equity-market exposure to those AI companies and price in a deceleration of earnings growth, noted Goldman.
Goldman sees still-solid earnings-per-share growth in 2027 - their baseline forecast calls for S&P 500 EPS to grow 36% in 2026, but slow to 11% in 2027. They estimate that AI capex is currently contributing about half of that EPS growth, which should fade in 2027 as capex growth slows and depreciation expenses build.
"In addition to pressure from interest rates and energy prices, slowing AI investment growth will be a fading tailwind," with early reads on the third-quarter supporting this view, the strategists said.
During the last four quarters, 64% of S&P 500 firms beat EPS consensus forecasts, but just 53% of firms have managed that for the third-quarter reporting season getting underway, said Goldman.
-Barbara Kollmeyer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-19-26 0558ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
10 Best Blue-Chip Stocks to Buy for the Long Term
